Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making

BMC Medical Research Methodology

Volumn 13, Issue 1, 2013, Pages

  Cope, Shannon ^a   Jansen, Jeroen P ^b  

^a MAPI GROUP   (Netherlands)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Network meta analysis; Probabilities; Rank; Survival

Indexed keywords

ARTICLE; BAYES THEOREM; DECISION MAKING; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS (TOPIC); PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

BAYES THEOREM; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84888347443     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-13-147     Document Type: Article

References (29)

1. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Dias S, Sutton AJ, Ades AE, Welton NJ, Med Decis Making 2013 33 5 607 617 10.1177/0272989X12458724 23104435
2. Indirect comparisons of competing interventions. Glenny AM, Altman DG, Song F, et al. Health Technol Assess 2005 9 1 134
3. Interpreting indirect treatment comparisons & network meta-analysis for health care decision-making: report of the ISPOR task force on indirect treatment comparisons good research practices-part 1. Jansen JP, Fleurence R, Devine B, et al. Value Health 2011 14 417 428 10.1016/j.jval.2011.04.002 21669366
4. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Song F, Altman DG, Glenny A, Deeks JJ, BMJ 2003 326 472 10.1136/bmj.326.7387.472 12609941
5. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Caldwell DM, Ades AE, Higgins JPT, BMJ 2005 331 897 900 10.1136/bmj.331.7521.897 16223826 (Pubitemid 41502718)
6. Use of indirect and mixed treatment comparisons for technology assessment. Sutton A, Ades AE, Cooper N, Abrams K, Pharmacoeconomics 2008 26 753 767 10.2165/00019053-200826090-00006 18767896
7. National Institute for Health and Clinical Excellence, Guide to the Methods of Technology Appraisal London: NICE 2008
8. Pharmaceutical Benefits Advisory Committee, Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory committee. (Version 4.3) Canberra: Australian Government, Department of Health and Ageing 2008
9. Wells GA, Sultan SA, Chen L, Khan M, Coyle D, Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis Ottawa: Canadian Agency for Drugs and Technologies in Health 2009
10. Combination of direct and indirect evidence in mixed treatment comparisons. Lu G, Ades AE, Stat Med 2004 23 3105 3124 10.1002/sim.1875 15449338 (Pubitemid 39334902)
11. Whither trial-based economic evaluation for health care decision-making? Sculpher M, Claxton K, Drummon M, McCabe C, Health Econ 2006 15 7 677 687 10.1002/hec.1093 16491461 (Pubitemid 44057239)
12. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Jansen JP, Crawford B, Bergman G, Stam W, Value Health 2008 11 5 956 964 10.1111/j.1524-4733.2008.00347.x 18489499
13. Graphical methods and numeric summaries for presenting results for multiple-treatment meta-analysis: an overview and tutorial. Salanti G, Ades AE, Ioannidis JPA, J Clin Epidemiol 2011 64 2 163 171 10.1016/j.jclinepi.2010.03.016 20688472
14. Network meta-analysis of parametric survival curves. Ouwens MJNM, Philips Z, Jansen JP, Res Synth Methods 2010 1 3-4 258 271
15. Network meta-analysis of survival data with fractional polynomials. Jansen JP, BMC Med Res Methodol 2011 11 61 10.1186/1471-2288-11-61 21548941
16. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. Jansen JP, Cope S, BMC Med Res Methodol 2012 12 152 doi:10.1186/1471-2288-12-152 10.1186/1471-2288-12-152 23043545
17. Survival analysis for economic evaluations alongside clinical trials- extrapolation with individual patient-level data. Latimer NR, Med Decis Making 2013 33 5 doi:10.1177/0272989X12472398
18. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. J Clin Oncol 2004 22 6 1118 1125 10.1200/JCO.2004.04.165 15020614 (Pubitemid 41095046)
19. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, et al. J Clin Oncol 1994 12 806 811 8151323 (Pubitemid 24110922)
20. Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. J Clin Oncol 1999 17 2745 2751 10561349 (Pubitemid 29415231)
21. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Chiarion SV, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L, et al. Melanoma Res 2001 11 2 189 196 10.1097/00008390-200104000-00015 11333130 (Pubitemid 32385824)
22. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, et al. New Engl J Med 1992 327 516 523 10.1056/NEJM199208203270803 1635566
23. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an eastern cooperative oncology group study. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH, J Clin Oncol 1998 16 1743 1751 9586887
24. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. Falkson CI, Falkson G, Falkson HC, J Clin Oncol 1991 9 1403 1408 2072144
25. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. J Clin Oncol 2000 18 158 166 10623706 (Pubitemid 30036349)
26. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Thomson DB, Adena M, McLeod GR, Hersey P, Gill PG, Coates AS, et al. Melanoma Res 1993 3 133 138 8518552 (Pubitemid 23156589)
27. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Young AM, Marsden J, Goodman A, Burton A, Dunn JA, Clin Oncol 2001 13 458 465 (Pubitemid 34071948)
28. Spiegelhalter D, Thomas A, Best N, Lunn D, WinBUGS User Manual: Version 1.4 Cambridge: MRC Biostatistics Unit 2003
29. Progression-free survival with Fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Cope S, Ouwens MJNM, Jansen JP, Schmid P, Value Health 2013 16 2 403 417 10.1016/j.jval.2012.10.019 23538193